Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosaprepitant (generic) vs Emend in prevention of CINV in HEC
CTR20171385Phase 3Completed
- Sponsor
- Jiuyuan Gene Engineering
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of aprepitant in chemotherapy-induced nausea and vomiting (CINV), sponsored by Jiuyuan Gene Engineering. Started Apr 2018; status: completed.
02
Drugs
aprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on CTR20171385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171385.